Business
EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
EQT Life Sciences is pleased to announce that Ipsen (Euronext: IPN; ADR: IPSEY) has entered into a definitive agreement to acquire its portfolio company ImCheck Therapeutics for EUR 350 million at closing, with a total transaction value of up to USD 1 billion.
About this update from Ipsen Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck's shareholders will be eligible to receive a payment of EUR 350 million and downstream payments, for a total potential consideration of up to EUR 1 billion.","length":256,"tagName":"p"}]},{"val":[{"type":"text","content":"ImCheck Therapeutics is a private French biotechnology company pioneering next-generation immuno-oncology therapies.","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"EQT Life Sciences has backed ImCheck since 2017 and has provided comprehensive support beyond capital, at the board level.","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"text","content":"STOCKHOLM, Oct. 22, 2025 /PRNewswire/ -- EQT Life Sciences is pleased to announce that Ipsen (Euronext: IPN; ADR: IPSEY) has entered into a definitive agreement to acquire its portfolio company ImCheck Therapeutics for EUR 350 million at closing, with a total transaction value of up to USD 1 billion.","length":301,"tagName":"p"},{"type":"text","content":"ImCheck Therapeutics, based in Marseille, France, is pioneering immuno-oncology therapies by targeting butyrophilins, a novel group of immune-regulating proteins. Its lead drug, ICT01, is being tested in acute myeloid leukemia (AML) patients who are not fit for standard treatment, with early Phase I/II trial results showing promising responses. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer.","length":475,"tagName":"p"},{"type":"text","content":"EQT Life Sciences invested in the business in 2017, as part of a syndicate of investors, and has since provided comprehensive support, including at the board level.","length":164,"tagName":"p"},{"type":"text","content":"Vincent Brichard, Venture Partner at EQT Life Sciences and board member at ImCheck Therapeutics, said: "We are immensely proud to have supported ImCheck's journey to this significant acquisition by Ipsen. The transaction highlights the strength of ImCheck's platform and exceptional leadership and team. It is also a testament to our ability to identify hidden gems and support transformative biotech companies."","length":430,"tagName":"p"},{"type":"text","conte...